Answers are grounded in this paper and cite their sources.
In patients with pulmonary fibrosis (PF), disease course, treatment response and quality of life differ sharply, so a single "standard" regimen is not enough. This review summarizes the 2022 ATS/ERS/JRS/ALAT recommendations on idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF), data on nerandomilast, approved in 2025, and models of patient-centered care. The individualized approach has five components: (1) precise phenotyping based on multidisciplinary discussion; (2) drug selection that takes into account the patient's goals, comorbidities and tolerability; (3) pulmonary rehabilitation, oxygen and nutritional support; (4) management of symptoms (cough, dyspnea, anxiety); and (5) introduction of palliative care and advance care planning from the early stages of the disease. The review offers clinicians a practical algorithm and identifies unresolved questions.
No takes yet. Share an insight, caveat, or question.
Adkhamov Dilmurodjon Dilshodjon ugli (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: